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Abstract 
Any new drug or biological product undergoes rigorous testing in animals and humans for 
review by the United States Food and Drug Administration (FDA) before it becomes 
available for human use. A sponsor files an investigational new drug (IND) application with 
the FDA with supporting animal data, after which testing is continued with humans. There is 
sufficient guidance from the FDA on new small molecules and biological products as to 
which preclinical studies are to be conducted. Synthetic peptides present a unique scenario in 
which a case-by-case approach is needed for the conduct of preclinical studies. For peptides 
containing components that are already tested for genotoxicity, it is unnecessary to reevaluate 
them. If such information can be shared with sponsors ahead of the IND application, it can 
save time and money. There is no research that evaluated the FDA’s views on pre-IND 
consultation. Therefore, through a 10-item questionnaire, FDA reviewers’ perceptions on 
pre-IND consultation, particularly synthetic peptides, were examined. Only four CDER FDA 
reviewers responded. Three reviewers stated willingness to provide advice to the sponsor 
through pre-IND discussion and to consult supervisory project managers. Two reviewers 
agreed that synthetic peptides are to be considered individually for genotoxicity purposes and 
that pre-testing consultation should be sought. Future research from a larger sample may 
provide insights on the perceptions of the FDA.  Information gleaned from previously 
approved peptides, however, indicates that there is a wide variability in the type of pre-
clinical studies submitted with an NDA (New Drug Application) before progressing to first-
in-human studies. However, the routinely submitted studies were single and repeat dose 
toxicity, genotoxicity, carcinogenicity, reproductive and developmental toxicity, and often 
studies for impurities. 
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Chapter 1: Introduction 
In the United States, the Food and Drug Administration (FDA) is the institutional 
body responsible for “protecting the public health by assuring the safety, effectiveness, 
quality, and security of human and veterinary drugs, vaccines and other biological products, 
and medical devices” (U. S. Food and Drug Administration, 2018d). Any drug or biological 
product that is developed for treatment or diagnostic purpose undergoes a rigorous review 
process by the FDA before it becomes approved for clinical use. A pharmaceutical firm that 
develops a drug is termed its sponsor. A recent report by the Tufts Center for the Study of 
Drug Development (2014), using the drug development data from 1995–2013 (from 10 
firms), indicated that approximately $2.6 billion is spent for each FDA-approved medicine 
that reaches the US market and that the process from synthesis to approval takes an average 
of 10 years. Out of 1,442 investigational compounds identified in the research, only 7.1% 
were approved, while 80.3% had been discontinued and 12.6% were still active by the end of 
2013. Of note, the research showed that a significant amount of time (nearly 31 months) and 
money (nearly 31% of the total expenditure) is spent during the preclinical phase, that is, the 
phase before the drug is tested in humans (Tufts Center for the Study of Drug Development, 
2014). 
Peptides are a unique class of drugs that structurally fall between small molecules and 
proteins and possess unique advantages of high specificity and low toxicity. The first peptide, 
insulin, was discovered in 1920, and more than 60 peptides have been approved for human 
use as of 2017 (Lau & Dunn, 2017). Technological advancements in the identification of new 
receptors and targets involved in disease pathogenesis have paved the way for increased 
research on peptides for management of disease. However, certain intrinsic properties such as 
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metabolic instability and the need for parenteral route of administration are major hurdles for 
peptide development. Chemically synthesized peptides overcome these challenges by the use 
of non-natural amino acids to improve the metabolic stability, or chemicals such as 
polyethylene glycols, are used to enhance membrane transportation (Groß, Hashimoto, Sticht, 
& Eichler, 2015). The most challenging phase for peptide development is the preclinical 
phase. As peptides do not reach the cellular targets by diffusion like small molecules and 
exert effects by binding to a cell surface receptor, the determination of their pharmacological 
and pharmacokinetic parameters through in vitro and in vivo assays is challenging. (Uhlig, 
2014). Although there are guidance documents for sponsors on recommendations for proteins 
(ICH S6) and small novel chemical entities (NCEs; ICH S1-S5, S7-S8, ICH M3), guidance 
specific to peptides is limited. Pre-investigational new drug interactions between sponsors 
and the FDA may help clarify regulatory issues. Given limited literature on the regulation of 
peptide drug products, this study intended to assess FDA opinions related to the preclinical 
testing of synthetic peptides. 
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Chapter 2:  Background 
Overview of Preclinical Studies Submitted with IND 
An investigational new drug (IND) typically consists of non-clinical and clinical 
components. Key non-clinical components include the preclinical data from the animal 
pharmacology and toxicology studies, and chemistry, manufacturing, and controls of the 
investigational drug. Clinical components contain the protocols for the proposed human 
studies and summaries of previous human experience, if any. Detailed information on the 
IND application is available in the 21CFR (Code of Federal Regulation) Part 312. 
Typically, non-clinical studies are conducted in order to  
• evaluate the mode of action of the treatment,  
• identify the safe starting dose and dose escalations for the first-in-human 
studies,  
• determine toxic doses and potential target organs,  
• assess whether the toxicities are reversible, and, finally,  
• determine which safety parameters are to be monitored in human studies 
(International Conference on Harmonization, 1997).  
The nonclinical studies submitted to an IND can be broadly categorized as 
pharmacokinetics, pharmacology, and animal toxicity studies.  In vivo testing includes 
relevant animal models to estimate the lowest dose for therapeutic efficacy (Maralee, 2014). 
Other non-clinical safety studies include single and repeated dose toxicity studies in two 
species, reproductive toxicity studies, genotoxicity studies, and studies for special safety 
concerns such as immunogenicity and carcinogenicity (International Conference on 
Harmonization, 2009). An overview of the preclinical studies typically conducted as a part of 
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drug development program is presented in the Table 1. The specific objectives of each type of 
non-clinical study and a few examples of each type of study are presented in Appendix A. 
Table 1 
List of Safety Studies 
Type of Safety Study Timing of the Study 
Acute Toxicity Prior to Phase 1, 2 and 3 
 
Sub-acute/Sub-chronic Toxicity In parallel with Phase I clinical studies 
 
Chronic Toxicity Concurrently with Phase III clinical trials 
Safety Pharmacology Prior to Phase 1 
Genotoxicity In vitro: Prior to Phase 1 
 
In vivo: Prior to Phase 2 
Developmental and Reproductive 
Toxicity 
 Prior to Phase 3  
 
Phase 1 clinical studies (in male volunteers) may start even 
without the development/reproductive toxicity data, if the 
treatment does not indicate any testicular damage in safety 
studies of 2 to 4 weeks’ duration  
Carcinogenicity During Phase II and III of clinical development.   
Usually required for drugs intended for continuous treatment 
for 6 months or more duration 
Note. From “Non-clinical studies in the process of new drug development: Part II: Good laboratory practice, 
metabolism, pharmacokinetics, safety and dose translation to clinical studies” by E. L. Andrade, A. F. Bento, 
J.Cavalli, S. K. Oliveira, R. C. Schwanke, J. M. Siqueira, C. S. Freitas, R. Marcon, and J. B. Calixto, 2016, 
Brazilian Journal of Medical and Biological Research, 49, p7–17; 
“Chapter 9: Animal use in toxicity studies”, The ethics of research involving animals. p. 155–167. London: 
Nuffield Council on Bioethics.  
Review Process at FDA 
Within the FDA, there are two centers for reviewing an IND application for a 
therapeutic product: the Center for Drug Evaluation and Research (CDER) and the Center for 
Biological Evaluation and Research (CBER). A sponsor will submit the IND to CDER or 
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CBER, depending on the scope of the regulatory supervision of these bodies. Small 
molecules are covered majorly by the CDER while biological products are primarily 
reviewed by the CBER (U. S. Food and Drug Administration, 2018b). In 2003, the FDA 
transferred the regulatory responsibilities for some therapeutic biological products to CDER. 
These products include monoclonal antibodies and proteins intended for therapeutic use, such 
as cytokines, enzymes, and other novel proteins, immunomodulators, and targeted biological 
treatments that alter the production of hematopoietic cells (U. S. Food and Drug 
Administration, 2018f). CDER/CBER reviews the information with an IND and accepts or 
rejects the IND (U. S. Food and Drug Administration, 2017d). In 2016, CDER received 
overall 1669 drug and novel biologic INDs (U. S. Food and Drug Administration, 2017c).  
 The CDER Offices of New Drugs consists of six Offices and a total of 19 review 
divisions that undertake the IND reviews. INDs are currently assigned to one review division 
from the following (U. S. Food and Drug Administration, 2018a): 
• Office of Drug Evaluation I – Division of Cardiovascular and Renal Products; 
Division of Neurology Products; Division of Psychiatric Products. 
• Office of Drug Evaluation II – Division of Metabolic and Endocrineo Products; 
Division of Pulmonary, Allergy, and Rheumatology Products; Division of Anesthesia, 
Analgesia, and Addiction Products. 
• Office of Drug Evaluation III – Division of Gastroenterology and Inborn Errors 
Products; Division of Bone, Reproductive, and Urologic Products; Division of 
Dermatology and Dental Products. 
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• Office of Drug Evaluation IV – Division of Nonprescription Clinical Evaluation; 
Division of Medical Imaging Products; Division of Pediatric and Maternal Health 
Products. 
• Office of Antimicrobial Products (OAP) – Division of Anti-Infective Products; 
Division of Antiviral Products; Division of Transplant and Ophthalmology Products. 
• Office of Hematology and Oncology Products (OHOP)– Division of Oncology 
Products (one and two); Division of Hematology Products; Division of Hematology 
Oncology Toxicology.  
FDA Review Process in Brief 
 When an IND application is received, the division director appoints the cross-
discipline team leader based on the content of application; most often the choice is a medical 
officer, who is also responsible for the review of clinical section (U. S. Food and Drug 
Administration, n.d.). The other review team members are  
• project managers, who are the primary contacts with the sponsor and who prepare the 
review plan, coordinate the review team activities, monitor the review status, 
maintain up-to-date information on milestones, and assure a timely review;  
• a medical officer, who reviews clinical studies; 
• a pharmacology/toxicology specialist, who reviews all nonclinical (animal) studies;  
• statisticians, who review protocols and the statistical analysis plan; 
• clinical pharmacology/biopharmaceutics reviewers, who evaluate pharmacokinetic 
and pharmacodynamics of the study drug; and 
• chemists, who evaluate drug chemistry, manufacturing and controls, stability profile, 
and other chemistry issues (U. S. Food and Drug Administration, 2015). 
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FDA Guidance for Sponsors 
The FDA recommends that sponsors follow the requirements in guidance documents 
published by the International Council for Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use (ICH). These documents can help formulate essential 
studies to be submitted with an IND to gain approval for first-in-human trials. The 
requirements for the conduct of each type on non-clinical studies are listed in specific ICH 
guidance documents, listed in Table 2, which also extends further (U. S. Food and Drugs 
Administration, 2018e; International Conference on Harmonization, 2009)  
 
Table 2 
List of ICH Guidance Documents by Type of Non-clinical Study 
Non-clinical Tests – Related ICH guidance ICH guidance document 
Pharmacokinetic Studies: 
 
Guidance on toxicokinetics: Assessment of 
systemic exposure in toxicity studies 
 
Guidance on pharmacokinetics: repeated 
dose tissue distribution studies 
 
 
ICH S3A  
 
 
ICH S3B 
Chronic Toxicity Studies: 
 
Guidance on duration of chronic toxicity 
testing in animals (rodents and non-rodent 
toxicity testing) 
 
 
ICH S4 
Genotoxicity Studies: 
 
Genotoxicity testing and data interpretation 
for pharmaceuticals intended for human use 
 
Guidance on assessment and control of DNA 
reactive (mutagenic) impurities in 
pharmaceuticals to limit potential 
carcinogenic risk  
 
 
ICH S2 (R1) 
 
 
ICH M7 
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Table 2 continued 
Carcinogenicity Studies: 
 
Guidance on  
• Need for carcinogenicity and  
• Testing for carcinogenicity of 
Pharmaceuticals 
• Dose selection for carcinogenicity 
studies of pharmaceuticals  
 
 
 
ICH S1A, S1B, S1C (R2) 
Safety Pharmacology Studies 
 
Guidance on  
• Safety pharmacology studies for 
human pharmaceuticals  
• Nonclinical evaluation of the 
potential for delayed ventricular 
repolarization (QT interval 
prolongation) by human 
pharmaceuticals 
 
 
ICH S7A, S7B 
Reproductive Toxicity Studies 
 
Guideline on Detection of Toxicity to 
Reproduction for Human Pharmaceuticals 
 
ICH S5 
Immunotoxicity Studies 
 
Guidance on immunotoxicity studies for 
human pharmaceuticals  
ICH S8 
Note. All guidance documents were developed within the Safety Implementation Working Group of the 
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. 
There are multiple opportunities for the drug sponsor to meet with the FDA team in 
the drug developmental process. Such interactions can help sponsors not only to reduce 
chances of IND rejection but also to learn of current issues. One such opportunity is the pre-
IND meetings. These can reduce time to market in many ways, such as by identifying and 
avoiding unnecessary studies, confirming designs of the needed studies, minimizing costs, 
and allowing early interactions/negotiations with the FDA. The pre-IND meeting request 
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must be submitted at least four weeks earlier than the scheduled date and along with a pre-
IND package containing all necessary background information and the list of questions that 
the sponsor requires the FDA to answer. Pre-IND meetings are useful for sponsors for studies 
with scientific or regulatory issues related to clinical trial design, toxicity, unique metabolites, 
non-standard or novel formulations, dosing limitations, species suitability, and 
immunogenicity (National Heart, Lung, and Blood Institute, 2013). There is a specific FDA 
guidance document that talks about the conduct of formal meetings (U. S. Food and Drug 
Administration, 2017b).   
Prior to a pre-IND meeting, the sponsor may also have an informal meeting with the 
FDA team, through a pre-pre-IND teleconference. This will not reduce the necessity of a pre-
IND meeting but can help the sponsor get possible solutions related to preclinical issues. For 
example, the selection of animal model for the preclinical study can be discussed (Feigal et 
al., 2012). 
Peptides and Synthetic Peptides 
Peptides have been a unique, rapidly growing class of treatments since the advent of 
insulin in the early 1920s (Banting, Best, Collip, Campbell, & Fletcher, 1922). Across the 
United States, Europe, and Japan, more than 60 peptide drugs were approved before 2017, 
and more than 150 are under active clinical development (Lau & Dunn, 2017). Peptides have 
been recognized as promising therapeutic agents for the treatment of various conditions such 
as cancer, and, metabolic, infectious, or cardiovascular diseases (Vlieghe, Lisowski, Martinez, 
& Khrestchatisky, 2010; Lau & Dunn, 2017). Special advantages that peptides show over 
other drugs include being highly versatile, target-specific, less toxic, and able to act on a 
wide variety of targets (Fosgerau & Hoffmann, 2015; Vlieghe et al., 2010), which are directly 
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responsible for greater success rate than small molecules (approval rate of around 20% 
versus 10%; Lax, 2013; Uhlig et al., 2014). The list of FDA approved peptides is presented in 
Appendix A (Usmani et al., 2017).  
Initially, life-saving peptides such as insulin and ACTH were isolated from natural 
sources. The feasibility of chemical synthesis of peptides in 1950s enabled the introduction 
of synthetic oxytocin and vasopressin. Further, the recent technological developments in the 
genomic era helped in identification and characterization of peptide hormone receptors, and 
novel ligands for these receptors are being actively explored (Feigal et al., 2012). 
The intrinsic limitations for peptides include metabolic instability, that is, the inability 
to withstand 600 proteases in the human body (Lopez-Otin & Matrisian, 2007) and restriction 
to the parenteral route of administration. Chemically synthesized peptides can overcome both 
of these challenges by incorporating additional entities, such as non-natural amino acids, to 
improve the metabolic stability, or other chemical entities, such as polyethylene glycols, to 
enhance membrane transportation (Groß et al., 2015). 
During the drug developmental process, the most challenging phase for peptides is 
the preclinical phase. Conventional smaller therapeutic molecules reach their cellular targets 
by diffusion, but peptides enter cells through the surface receptors, and therefore, 
determining their in vitro and in vivo pharmacology from immunological assays becomes 
challenging (Uhlig et al., 2014). For example, 4F peptides have demonstrated potent anti-
inflammatory, anti-oxidant, and atheroprotective effects in preclinical models of apoE null 
mice and in human aortic cell cultures but failed to show the same effects in human trials. 
This could be attributed to the differences in the composition of lipid-associated proteins 
between humans and mice (Recio, Maione, Iqbal, Mascolo, & De Feo, 2016). Peptide-based 
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therapeutics have a higher chance of clearing the early clinical trials than other drugs, once 
they overcome the IND hurdles (Otvos, 2014).  
Importance of FDA guidance on preclinical studies of synthetic peptides. 
Peptides fall under a distinct category of treatments, and there is no FDA guidance specific to 
the preclinical testing of peptides. The current biopharmaceutical guidance documents are 
used to determine the recommended battery of essential preclinical tests. The ICH S6 
consists of recommendations for biological therapeutics while other documents, such as ICH 
S1-S5, S7-S8, ICH M3, are for smaller molecule drugs. The areas of uncertainty for peptide 
drug development, for which a pre-IND consultation would greatly help, are described below. 
Species selection. Typically, it is recommended that toxicology testing be performed 
in two different species; the most commonly used are rats and dogs (Kingham, Klasa, & 
Carver, 2010). As biologics show tissue-specific activity, conducting such studies in a 
pharmacologically irrelevant species will be inappropriate. In those cases, sponsors may 
utilize homologous proteins or transgenic animals that express human receptor or other 
animal models (Kingham et al., 2010).  
Immunogenicity is another factor for species selection, particularly for vaccine 
peptides. Sponsors should always note that animal data are not truly indicative of human 
immune response. Elevated antibody production during repeat-dose toxicity studies may not 
necessarily be the rationale for the termination of the preclinical studies unless observed in a 
large proportion of animals (Kingham et al., 2010). 
Genotoxicity. Previously, in a typical small molecule preclinical testing approach, 
genotoxicity testing was often conducted. However, recent regulatory guidance documents 
have been amended and now state that genotoxicity testing is not necessary with biological 
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products. This is because they are not directly associated with any known genetic toxicity 
risk (International Conference on Harmonization, 2011). But in instances where the biologic 
product has any molecule with such risk, genetic toxicity testing might be needed 
(Vugmeyster, Xu, Theil, Khawli, & Leach, 2012). 
Synthetic peptides present a special scenario for genotoxicity testing. If the test 
peptide contains exclusively natural amino acids, testing may not be necessary. Also, testing 
may not be necessary for peptides that contain already tested non-natural amino acids, linkers, 
and non-linker components. However, if such peptides have been modified for better cellular 
absorption, the in vivo genotoxicity testing may be necessary. Linkers that can be potentially 
mutagenic impurities need to be evaluated as per ICH M7 (Thybaud et al., 2016). Testing for 
such process-related impurities is the key difference between the biotechnologically-derived 
and chemically-synthesized peptides (Heidel & Page, 2010).  
Pre-IND and “pre-pre-IND” meetings are the best opportunities for the sponsors to 
discuss any preclinical issues with the FDA before IND filing. These meetings can help 
sponsors provide adequate information with the IND and avoid clinical holds from the FDA 
(Feigal et al., 2012). 
Purpose of the Study 
Although many published sources recommended that pre-IND consultation would be 
beneficial for sponsors to aid the therapeutic biologic development process, there is no 
research that captured the FDA’s perspective on this issue. Synthetic peptides have been a 
key research area in recent years with several preclinical issues, as highlighted in previous 
sections. Any direct evidence captured from the FDA reviewers’ viewpoint could further help 
sponsors plan better for the consultation program. Hence, this study was conducted to assess 
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FDA opinions related to synthetic peptides in two ways. First, a survey was conducted to 
understand the FDA reviewers’ responses to the questions related to the conduct of 
preclinical studies, with some specifically on synthetic peptides. Second, FDA 
documentation was reviewed to summarize the non-clinical studies from the recently 
approved synthetic peptides.  
Research Questions 
The first part of the study aimed to address the following through this survey:  
• What are the preclinical toxicology requirements for synthetic peptides? 
• How can researchers obtain input? 
• What suggestions might FDA reviewers have to resolve this question? 
The second part of the study aimed to address the following:  
• What non-clinical studies have been submitted with INDs for recently 
approved synthetic peptides? 
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Chapter 3: Methods 
Part 1 – Online Survey of FDA Reviewers 
The study used an e-mail survey with a 10-item multiple-choice questionnaire. As this 
research focused on understanding the perceptions of the FDA on regulatory issues of 
synthetic peptides, FDA reviewers were considered the targeted study population. In the 
questionnaire, the first three items captured the background profile and experience of the 
FDA employee. The next seven items included specific questions related to the synthetic 
peptides. Appendix B contains the questionnaire. Space was left at the end of the 
questionnaire for free text suggestions or feedback from survey participants. 
The survey questions were uploaded into the Google survey tool, Google forms, and 
the link was saved by the researcher. After receiving the approval of the University Human 
Subjects Review Committee at Eastern Michigan University (Appendix C), the Google form 
link with the survey questions was forwarded to one of the FDA employees. This employee 
later directed it individually to other FDA employees, from his contacts in the FDA, via their 
official e-mail IDs. Overall, the questionnaire was forwarded to approximately eighty FDA 
reviewing or supervisory pharmacologists. 
Part 2 – Review of Previously Submitted Non-Clinical Studies 
In the second part of the study, data from two recent review articles by Vlieghe and 
colleagues (2010), and Lau and Dunn (2017) that contained the names of approved synthetic 
peptides across the world were reviewed. In the review article by Vlieghe et al. (2010) the 
authors tabulated the information on peptides approved in the US, Europe, and Japan, with 
specific details on peptide length (number of amino acids) and sequence, and the specific 
indications. In the review article by Lau and Dunn (2017), the authors also summarized the 
PRECLINCAL TESTING OF SYNTHETIC PEPTIDES      15 
status in the US, Europe, and Japan on approved peptides, as well as their route of 
administration and targeting receptors in the supplementary table of the published paper. 
Each peptide identified from the two articles was then checked for US approval dates, 
number of amino acids, manufacturing process, and whether synthetic or not, from the FDA 
website (U. S. Food and Drug Administration, 2018c) and the Drug Bank online database 
(DrugBank, 2018). For the current research, any polymer with 40 or fewer amino acids was 
considered a peptide, as adopted by the FDA. Of them, only synthetic peptides with 40 or 
fewer amino acids approved by FDA composed the peptide set of interest for this study. 
For synthetic peptide drugs approved between 2007 and 2017, the non-clinical 
pharmacology review information was obtained from the FDA website (U. S. Food and Drug 
Administration, 2018c). From each PDF document, information with respect to non-clinical 
studies was extracted and summarized.  
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Chapter 4: Results 
Part 1 – Online Survey of FDA Reviewers 
Of the 80 recipients of the questionnaire email, only four FDA reviewers responded. 
The survey responses are presented in Table 3. Out of four, three respondents were reviewing 
pharmacologists and one was a supervisory reviewer. All of them were reviewers at the 
CDER. Experience at the FDA was more than 10 years for three respondents, while a single 
respondent’s experience was between 6 and 10 years. 
Most reviewers were willing to provide advice to sponsors prior to submission but 
only with a pre-IND meeting request, whereas one reviewer was against providing any 
informal advice. Two preferred face-to-face conversation as the best way of communication 
with sponsors regarding any advice. Three of the four respondents recommended contacting 
the supervisory project manager for advice. Two respondents agreed that pre-testing 
consultation was necessary for synthetic peptides and that each compound should be treated 
separately. Also, two reviewers suggested that more than two months’ time should be allowed 
for receiving input from the FDA before beginning toxicology tests of synthetic peptides. All 
of the reviewers agreed that pharmacological differences between human and animal models 
are a concern for selection of species for toxicological studies. In that case, two reviewers 
recommended pre-testing consultation with FDA, while two stated that animals should 
exhibit the same pharmacology as humans for toxicity testing. Finally, two reviewers claimed 
to have had personal experiences in dealing with issues pre-IND, but not as the specific ones 
mentioned in the survey. One reviewer had an experience similar to those in the 
questionnaire. 
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Table 3 
Responses to the Survey 
Question n % 
1. Position at FDA   
Reviewing Pharmacologist 3 75% 
Supervisory Pharmacologist 1 25% 
2. Review Center   
CDER 4 100% 
3. Years at FDA   
6 to 10 1 25% 
Greater than 10 3 75% 
4. Are you willing/able to provide informal advice to sponsors prior to 
submission of an IND?   
Yes, but a pre-IND meeting request and supporting documentation must be 
submitted 3 75% 
No, an active IND must be on file 1 25% 
5. The best way to obtain advice prior to IND submission is via   
Teleconference to discuss previously submitted materials 1 25% 
Face-to-face meeting to discuss previously submitted materials 2 50% 
Email replies from a reviewer to very specific questions 1 25% 
6. The appropriate contact to request pre-IND advice is   
The supervisory project manager 3 75% 
Any divisional project manager 1 25% 
7. Synthetic peptides should be considered, for genotoxicity purposes   
To be handled like a biologic product 1 25% 
To vary by compound. Pre-testing consultation should be sought 2 50% 
Unknown 1 25% 
8. If human synthetic peptides or biologics do not show the same 
pharmacology in animal models as they do in human tissue cultures, is this a 
concern for selection of species for toxicology testing? 
 
 
Yes, the animal model used for toxicity testing must exhibit the same 
pharmacology as that expected in humans 2 50% 
Pre-testing consultation with the Review Division should be sought 2 50% 
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Table 3 continued 
Question n % 
9. If pre-testing consultation is required before beginning toxicology test, 
how much time should be the sponsor build into their planning to allow 
appropriate input from agency?   
1 month 1 25% 
2 months 1 25% 
More than 2 months 2 50% 
10. Have you had personal experience dealing with issues like those 
mentioned in this survey?   
Yes for issues pre-IND, but not those specific ones mentioned here. 2 50% 
Yes  1 25% 
No 1 25% 
 
Part 2 – Review of Previously Submitted Non-Clinical Studies 
Out of more than 60 approved peptide drugs identified from the two papers, the final 
set included 41 peptides that were chemically synthesized, approved by the FDA, and had 40 
or fewer amino acids. These peptides are listed in Table 4. 
Table 4  
FDA-Approved Synthetic Peptides 
S. No 
Synthetic 
peptide drug 
FDA 
approval 
year 
Number 
of amino 
acids 
Indication Status 
1 Corticotropin 1950 39 Diagnosis - adrenocortical insufficiency Discontinued 
2 Lypressin 1961 9 Central diabetes insipidus, Cushing’s syndrome Discontinued 
3 Tetracosactide 1970 24 Diagnosis - adrenocortical insufficiency Prescription 
4 Desmopressin 1978 9 
Central diabetes insipidus, nocturnal enuresis, 
nocturia, and stoppage of bleeding or hemorrhage in 
haemophilia A patients 
Prescription 
5 Oxytocin 1980 9 
Initiation or improvement of uterine contractions, and 
control postpartum hemorrhage 
Prescription 
6 Saralasin acetate 1981 8 Hypertension Discontinued 
7 Gonadorelin 1982 10 
For evaluating gonadotropes of the anterior pituitary 
and residual gonadotropic function of the pituitary 
following therapy 
Discontinued 
8 Enalapril 1985 3 Hypertension Prescription 
9 
Calcitonin 
salmon 
1986 32 
Postmenopausal osteoporosis, Paget’s disease, 
hypercalcaemia 
Prescription 
10 
Calcitonin 
(human) 
1986 32 
Postmenopausal osteoporosis, Paget’s disease, 
hypercalcaemia 
Discontinued 
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Table 4 continued 
S. No 
Synthetic 
peptide drug 
FDA 
approval 
year 
Number 
of amino 
acids 
Indication Status 
11 Lisinopril 1987 3 
Acute myocardial infarction, heart failure, 
hypertension 
Prescription 
12 
Octreotide 
Acetate 
1988 8 Acromegaly, neuroendocrine tumors Prescription 
13 Goserelin 1989 10 Advanced prostate cancer, breast cancer Prescription 
14 Nafarelin  1990 10 
Central precocious puberty, endometriosis, uterine 
fibroids, ovarian stimulation in in vitro fecundation 
Prescription 
15 Histrelin 1991 9 Advanced prostate cancer, central precocious puberty Prescription 
16 Glatiramer 1996 
Random 
mixture 
Relapsing-remitting multiple sclerosis Prescription 
17 Eptifibatide 1998 7 
Acute coronary syndrome, unstable angina undergoing 
PCI 
Prescription 
18 Ganirelix 1999 10 
Inhibition of premature leutinizing hormone surges in 
controlled ovarian hyperstimulation 
Prescription 
19 Triptorelin 2000 10 
Advanced prostate cancer, central precocious puberty, 
endometriosis, uterine fibroids, ovarian stimulation in 
in vitro fecundation 
Prescription 
20 Cetrorelix 2000 10 
Inhibition of premature LH surges in women 
Undergoing controlled ovarian stimulation 
Prescription 
21 Bivalirudin 2000 20 
Anticoagulant for unstable angina patients undergoing 
angioplasty 
Prescription 
22 
Leuprolide 
acetate 
2002 9 
Advanced prostate cancer, breast cancer, central 
precocious puberty 
Prescription 
23 Abarelix 2003 10 Advanced prostate cancer Discontinued 
24 Enfuvirtide 2003 36 AIDS Prescription 
25 Ziconotide 2004 25 Severe chronic pain Prescription 
26 Pramlintide 2005 37 Type 1 and 2 diabetes Prescription 
27 Exenatide  2005 39 Type 2 diabetes mellitus Prescription 
28 Lanreotide 2007 8 Acromegaly, carcinoid syndrome Prescription 
29 Degarelix 2008 10 Advanced prostate cancer Prescription 
30 Liraglutide 2010 31 Type 2 diabetes Prescription 
31 Icatibant 2011 10 Hereditary angioedema Prescription 
32 Lucinactant  2012 21 Neonatal respiratory distress syndrome Discontinued 
33 Linaclotide  2012 14 
Constipation-dominant irritable bowel syndrome, 
chronic idiopathic constipation 
Prescription 
34 Pasireotide 2012 6 
Cushing’s disease, specifically for patients not eligible 
for pituitary surgery 
Prescription 
35 Carfilzomib  2012 4 
Progressive multiple myeloma after treatment with 
bortezomib and an immunomodulatory agent 
Prescription 
36 Etelcalcetide  2017 7 
Secondary hyperparathyroidism in chronic kidney 
disease patients on hemodialysis 
Prescription 
37 Plecanatide  2017 16 Chronic idiopathic constipation Prescription 
38 Abaloparatide 2017 34 Postmenopausal osteoporosis  Prescription 
39 Semaglutide 2017 31 Type 2 diabetes mellitus Prescription 
40 Macimorelin 2017 2 Diagnosis - adult growth hormone deficiency Prescription 
41 Angiotensin II 2017 8 
Increase blood pressure in patients with sepsis or other 
critical conditions 
Prescription 
Note. From “Synthetic therapeutic peptides: science and market” by P. Vlieghe, V. Lisowski, J. Martinez, and 
M. Khrestchatisky, 2010, Drug Discovery Today, 15, p. 40‒56; 
“Therapeutic peptides: historical perspectives, current development trends, and future directions” by J. L. Lau 
and M. K. Dunn, 2017, Bioorganic & Medicinal Chemistry, 26, p. 2700‒2707; 
“Therapeutic peptides” by F. Albercio and H. Kruger, 2012, Future Medicinal Chemistry, 4, p. 1527‒31;  
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“2017 FDA peptide harvest” by O. Al Musaimi, D. Al Shaer, D. L. Torre, and F. Albericio, 2018, 
Pharmaceuticals (Basel), 11, p. 7. 
Among the listed peptides, the 14 that were approved between 2007 and 2017 
(lanreotide, degarelix, liraglutide, icatibant, lucinactant, linaclotide, pasireotide, carfilzomib, 
etelcalcetide, plecanatide, abaloparatide, semaglutide, macimorelin, and Angiotensin II) were 
further researched by an examination of the non-clinical FDA reviews. There was a non-
uniform distribution of the FDA approvals over the time period of 2007–2017: three were 
approved between 2007–2010, five approved between 2011–2012, and six approved in 2017. 
No synthetic peptides were approved in the years 2013–2016. The ideal way to present such 
heterogenous non-clinical study data is through tables and a maximum of only four could be 
accommodated in one table. Hence, these safety studies submitted with the NDA (New Drug 
Application) for these peptides summarized in Tables 5–8 in a chronological order: Table 5 
for peptides approved in 2007–2010, Table 6 for those approved in 2011 and 2012 (excluding 
lucinactant), and Tables 7 and 8 for those approved in 2017 (three peptides as Part A and 
three peptides as Part B).  For the majority of these peptides, the following categories of 
general toxicology studies were conducted: single-dose toxicity, repeat-dose toxicity, 
genotoxicity, carcinogenicity, reproductive and developmental toxicity, and special 
toxicology studies. 
The series of non-clinical tests for Lucinactant were not included in Tables 5–8, since 
the non-clinical tests were very different from all other synthetic peptide drugs considered. 
Lucinactant was an intratracheal drug with targeted place of action (lungs) to treat acute 
respiratory distress in neonates. The non-clinical program of lucinactant included the 
following toxicology studies:  single dose in newborn rabbits, 7 days in adult rats, 4 days in 
rabbits, 14 days in newborn rabbits, a single dose in premature monkeys, immunogenicity in 
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monkeys, and systemic anaphylaxis in guinea pigs, preterm lambs, and fetal rabbits assay. 
The drug has been discontinued, however, to support the development of another aerosolized 
KL4 surfactant for the same indication by the sponsor (Windtree Therapeutics, 2015).
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Table 5 
Safety Studies of Synthetic Peptides Approved Between 2007 and 2010 
 Lanreotide Degarelix Liraglutide 
Single Dose Mice, rats (previous*) Mice, rats, monkeys Mice, rats 
Repeat Dose    
1 week   Rats 
2 weeks  Rats, monkeys Monkey 
4 weeks  Rats, monkeys Mice, rats, monkeys 
13 weeks  Rats, mice Mice, rats, monkeys 
26 weeks 
Rats, dog (previous*) 
Rats, dog (new formulation) 
Rats Rats 
52 weeks   Monkeys 
24 months Dog (previous*)   
Genetic Toxicology tests    
Ames test S. typhi and E.coli (previous*) S. typhi and E.coli S. typhi and E.coli 
In vitro DNA damage 
in mammalian cells 
Cultured human peripheral lymphocytes 
(previous*),  
L5178Y/TK+/- mouse lymphoma cells 
L5178Y/TK+/- mouse lymphoma cells Cultured human peripheral lymphocytes 
In vivo test for genetic 
damage 
Mouse micronucleus tests (previous*) Rat micronucleus tests Rat micronucleus tests 
Other genotoxicity tests Mutations in tissues of Muta™ Mice   
Carcinogenicity 104 weeks rats, mice 104 weeks rats, mice 104 weeks rats, mice 
Reproductive toxicology    
Segment 1 – Fertility Rats (previous*), Rats (present) Rats  
Dose range finding Rats, rabbits (previous*)  Rabbits 
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Table 5 continued 
 Lanreotide Degarelix Liraglutide 
Segmental (1/2) - 
reproductive  
 Rats Rats 
Segment 2 - teratology Rats, rabbits (previous*)  Rabbits 
Pre- and Post-natal 
Development 
 Rats, rabbits Rats 
Other Tests  None  
Local toxicity Rabbits, monkeys, minipigs  Pigs 
Mechanistic studies   For t-cell tumors 
Impurities   4 weeks rat toxicity study 
Other studies   
Toxicology studies with exenatide for 
comparison 
    
Note. IND, investigational new drug; NDA, new drug application. 
*“Previous” refers to studies submitted with previous IND submission or NDA submissions for the same molecule. 
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Table 6 
Safety Studies of Synthetic Peptides Approved During 2011–2012 
 Icatibant Linaclotide Pasireotide Carfilzomib 
Single Dose Mice, rats, dog (previous*) Rats, monkeys Mice, rats Rats, Monkeys 
Repeat Dose     
5 days   Rats, dog Monkeys 
1 week   Rats  
2 weeks Rats Rats, monkeys Mice, rats, dog, monkeys  
3 weeks    Rats 
4 weeks Dogs 
Mice (Common study for 
drug and impurities) 
Monkey, mice, rats 
Monkeys 
13 weeks Rats, dogs Mice, rats, monkeys  Rats 
26 weeks  Mice Rats Rats 
39 weeks  Monkeys Monkeys Monkeys 
Dose Ranging Study Dogs  Rats, monkey (2 week)  
Genetic Toxicology tests     
Ames test S. typhi S. typhi, E coli S. typhi  S. Typhi and E. coli 
In vitro DNA damage 
in mammalian cells 
Cultured human lymphocytes Cultured human lymphocytes Cultured human lymphocytes Cultured human lymphocytes 
In vivo test for genetic 
damage 
Rat micronucleus test None Rat micronucleus test Mouse micronucleus test 
Other genotoxicity tests  None   
Carcinogenicity None 104 weeks rats, mice 
104 weeks rats,  
6 months transgenic mice  
No carcinogenicity studies as 
per ICH S9 
Reproductive toxicology     
Segment 1 – Fertility  Rats  Rats  
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Table 6 continued 
 Icatibant Linaclotide Pasireotide Carfilzomib 
Dose range finding 
(Segment 2) 
  Rats, rabbits  
 
Segment 2 - teratology Rats, rabbit (previous*) Mice, rats, rabbits Rats, rabbits Rats, rabbits 
Segment 3 - Pre- and 
Post-natal 
Development 
Rats Rats  Rats 
 
Fertility and early 
embryonic 
Combined with 13-week 
toxicity test 
 
In vitro assessment using rat 
whole embryo culture 
 
Other Tests     
Local toxicity Rabbit  
Ocular rabbit, dermal rabbit, 
Rabbit/rat IM tolerance 
 
 In vitro hemolysis test  Rat immunotoxicity  
 
Hyperimmunization studies 
in the rat, dog and 
monkey 
  
 
Impurities 
For two degradants, in mice, 
single dose study 
Safety qualification of 
impurities – IV toxicity test, 
Ames test, Chromosome 
aberration test 
4-week toxicity for 
impurities, Ames test for 
impurities (also mentioned 
above) 
4-week toxicity test for 
impurities, Ames test for 
impurities, Chromosome 
aberration test for impurities 
 
Others  
Tested in juvenile mice and 
juvenile rabbits 
Phototoxicity 
Three-part study to 
investigate effect of 
proteasome inhibition on 
endotoxin challenge in mice 
Note. IND, investigational new drug; NDA, new drug application. 
* “Previous” refers to studies submitted with previous IND submission or NDA submissions for the same molecule. 
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Table 7 
Safety Studies of Synthetic Peptides Approved in 2017 – Part 1 
 Plecanatide Abaloparatide Etecalcitide 
Single Dose Mice, monkeys, rats Mice, rats Not conducted 
Repeat Dose    
5 days Mice, Monkeys (3 days) Monkeys (3 days)  
1 week Mice, rats (7/14 days)  Rats, Dogs 
2 weeks Rats (7/14 days), monkey   
4 weeks Mice, monkeys Rats, monkeys Rats, Dogs 
13 weeks Mice, rats, monkeys Rats, monkeys Rats, Dogs 
26 weeks Mice Rats Rats, Dogs 
39 weeks Monkeys Monkeys Dogs 
Genetic Toxicology tests    
Ames test E.coli, S.typhi E.coli, S. typhi, S.typhi and E.coli strains 
In vitro DNA damage 
in mammalian cells 
L5178Y/TK+/- mouse lymphoma cells 
Cultured human peripheral 
lymphocytes 
Cultured human peripheral 
lymphocytes, CHO-K1 cells, Chinese 
hamster lung fibroblast (V79) cells 
In vivo test for genetic 
damage 
Mouse micronucleus test Mouse micronucleus test Rat micronucleus test 
Other genotoxicity tests   4 week muta™ mouse test 
Carcinogenicity 104 weeks rats, mice 104 weeks rats 
104 weeks rats,  
6 months transgenic mice  
Reproductive toxicology    
Segment 1 – Fertility Mice Rats Rats (combined Segment 1, 2) 
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Table 7 continued 
 Plecanatide Abaloparatide Etecalcitide 
Dose range finding 
(Segment 2) 
Mice, rabbits  Rats, rabbits 
Segment 2 - teratology Mice, rabbits  Rats, rabbits 
Pre- and Post-natal 
Development 
Mice  Rats 
Other Tests  Phototoxicity  
Local toxicity  Local tolerance – rabbit, rat, monkey Dogs 
 
Juvenile toxicity – mice, single dose, 7 
days, 14 days, 14 or 13 weeks 
 Hemolysis testing blood 
Impurities  
Rats (2 weeks, 4 weeks) with unknown 
degradant, standard battery of 
genotoxicity for impurities 
4 weeks rats for mixture and 
impurities, 4 weeks dogs comparing 2 
lots, Ames test for sodium isopropyl 
sulphate 
Mechanistic Studies   
1.etelcalcetide and structurally related 
peptides were evaluated for mutagenic 
activity, 2. For metabolite formation, 3. 
L-cysteine for mutagenic potential, and 
3 more studies on mutagenicity 
Antigenicity Rabbits (105 days, 136 days)   
Note. IND, investigational new drug; NDA, new drug application. 
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Table 8 
Safety Studies of Synthetic Peptides Approved in 2017 – Part 2 
 Semaglutide Macimorelin  Angiotensin-II 
Single Dose Mice, rats (previous*) Rats, dogs Rats (Lit Search) 
Repeat Dose   Rats, rabbits (Lit Search) 
5 days  Rats, dogs  
2 weeks Mice (previous*), Monkey (previous*) Rats  
4 weeks Rats  Rats, dogs  
13 weeks 
Rats, Mice, rats (previous*), monkey 
(previous*) 
  
26 weeks Rats   
52 weeks Monkeys   
Dose Ranging Study 
8-18 days mice (previous*) 
14-25 days (previous*) 
  
Genetic Toxicology tests   Lit Search 
Ames test E. coli, S. typhi (previous*, present) S. typhi (previous*)  
In vitro DNA damage 
in mammalian cells 
Cultured lymphocytes (previous*, present) 
L5178Y T/K+/- mouse lymphoma 
cells, CHO-K1 cells 
 
In vivo test for genetic 
damage 
Rat micronucleus test Not conducted  
Other genotoxicity tests  
DEREK evaluation and MCASE 
evaluation for mutagenicity and 
genotoxicity of macimorelin and 
impurities 
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Table 8 continued 
 Semaglutide Macimorelin  Angiotensin-II 
Carcinogenicity 
Rats, mice – 2 year 
In vitro GLP-1R activation in rat thyroid C 
cell-line 
Mice (single dose), Rats (6 weeks dose) for 
calcitonin levels 
Not done as it is single dose 
product and the drug 
pharmacology/toxicology is known 
Lit search 
Reproductive toxicology  
Not done as it is single dose 
product and the drug 
pharmacology/toxicology is known 
Lit Search 
Segment 1 – Fertility Rats   
Segment 2 - 
teratology 
Rats, rabbit, monkey, rats (juvenile toxicity) 
rabbit (previous*) monkey (previous*), 
juvenile toxicity (previous*, animal not 
mentioned) 
  
Pre- and Post-natal 
Development 
Monkey   
Other Tests    
Local toxicity Pigs (previous*), rabbits (previous*)   
Mechanistic Studies 
For embryotoxicity to explore species 
specificity  
Conducted whole embryo cultures and 
studies in yolk sacs of untreated rats, 
monkeys 
  
Note. IND, investigational new drug; NDA, new drug application. 
PRECLINCAL TESTING OF SYNTHETIC PEPTIDES                           30 
*“Previous” refers to studies submitted with previous IND submission or NDA submissions for the same molecule. 
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Chapter 5: Discussion 
Part 1 – Online Survey of FDA Reviewers 
All of the survey respondents were well experienced, with 6 or more years of 
association with the FDA; hence, their thoughts on the survey questions are likely 
representative of FDA pharmacologists. Three of four reviewers agreed to provide informal 
advice to sponsors through a pre-IND meeting and supporting documentation, highlighting 
the significance of such meetings. However, there are no published data that present the 
number/proportion of sponsors approaching FDA for a pre-IND meeting advice. Of the four, 
only one reviewer agreed that teleconferencing was the best way to obtain advice prior to 
IND submission. This may imply that pre-pre-IND meetings, which are usually conducted 
through teleconferences, may not be of great value to the sponsors. There are some specific 
advantages for a telephonic conference over the face-to-face meeting: Scheduling is easier, 
and it is cheaper and more accessible to staff (Yetter, 2005). Two of the four reviewers 
recommended that meeting face-to-face is the best way. Face-to-face meetings are preferred 
only if such type of interaction is warranted, such as in case of issues concerning scientific, 
clinical, and regulatory aspects of the new products (Novak, Ruckman, & Trent, 2009). The 
sponsor can request a meeting and the FDA can take a call to provide a written response or 
accept a face-to-face meeting based on the questions posed to the FDA (Vaknalli, 2017). A 
majority (3/4) of the respondents agreed that the appropriate contact to request pre-IND 
advice was the supervisory project manager. The FDA guidance document that consists of 
best practices for communications between sponsors and FDA mentioned that the regulatory 
project manager is the ideal primary point of contact (U. S. Food and Drug Administration, 
2017a).  
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In the questions specific to synthetic peptides, two of the four CDER reviewers 
suggested that the synthetic peptide evaluation needs to vary by compound and that pre-
testing consultation should be sought. This is inconsistent with the article by Thybaud et al.  
(2016), in which the genotoxicity was described as being assessed only in the presence of 
non-natural amino acids or linkers or other components that were not previously assessed for 
genotoxicity. As such information gets updated frequently, meeting the FDA before toxicity 
testing can greatly help eliminate unnecessary studies and confirm the study design. Related 
to the question on the use of animal models for toxicology testing of synthetic peptides, two 
reviewers agreed that pre-testing consultation should be sought when human tissue cultures 
and animal models do not exhibit same pharmacology. Two reviewers answered by saying 
that animal models should show the same pharmacology. In cases when there are 
pharmacologically irrelevant species, there are alternatives: performing tests in only the 
relevant species, use of transgenic animals, and so on. These can be discussed in a pre-IND 
consultation to determine which tests can be performed. To the question on a timeline for 
getting input from the agency, three reviewers stated that a period of at least 2 months before 
beginning the toxicology tests was reasonable for appropriate input from the FDA. As per the 
FDA meeting guidance, pre-IND meetings need to be scheduled within 60 days of the day of 
receipt of the sponsor’s meeting request. However, the time limit for sponsors to share the 
materials is 30 days before the meeting, which leaves the agency with only 30 days to review 
the submitted materials. The minutes will be shared with the sponsor within 30 days (U. S. 
Food and Drug Administration, 2017b); only after this time can studies be initiated. So, it 
would be ideal for sponsors to allow more than 2 months before toxicity testing. Finally, 
three of the four reviewers had personal experiences related to a pre-IND issue, thus 
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highlighting the criticality of a pre-IND consultation. Therefore, every sponsor should 
seriously consider reaching out to the FDA for a pre-IND consultation program, which can 
eventually smooth the approval of IND. 
Reasons for a Low Response Rate 
This study had a very low response rate of only 5%. Many reasons can be suggested 
for this. The FDA is an institutional body with stringent rules. Employees were strictly 
prohibited from accessing third party emails; hence, the researcher’s FDA liaison forwarded 
the survey link to the personal mail IDs of interested participants. Many times employees 
may not have a chance or the time to respond to a survey received on their personal mail 
accounts. 
There was no possibility for the researcher to personally meet the FDA reviewer staff. 
Hence, the seriousness, depth, confidentiality, and purpose of the survey could not be 
communicated. If this had been done, it may have slightly improved the response rate.  
Based on this researcher’s personal experience of working in pharmaceutical 
industries, it appears that FDA responds to emails of pharmaceutical submissions. Meeting in 
person is a challenge for companies as well because the FDA insists on having a pre-
appointment booked, and only then will it respond. Being a student, the privilege of having 
an email account with a pharmaceutical company was nonexistent, so working for an 
academic institute and choosing this concept for study was the major setback that resulted in 
a poor response rate.   
Part 2 – Review of Previously Submitted Non-Clinical Studies   
In the second phase of the research, non-clinical studies submitted for synthetic 
peptides approved between 2010 and 2017 were evaluated for patterns in similarities and 
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differences. Apart from Lucinactant, a synthetic peptide containing surfactant for use in acute 
respiratory distress syndrome in neonates, all studied peptides had similar general safety 
studies or evidence submitted with their application for marketing approval. Another general 
observation was that no non-clinical studies were conducted for angiotensin-II because this 
was an exogenously administered endogenous hormone (human form) with well-known 
pharmacological action. Hence, upon the FDA’s request, the sponsor submitted targeted 
literature research summaries for all non-clinical safety study categories. 
The major species for conducting single dose toxicity for the included synthetic 
peptides was the rat, followed by mice and monkeys. Single-dose toxicity was studied in 
dogs for only icatibant and macimorelin. No single-dose toxicity study was conducted for 
etecalcitide, although no specific explanation was provided in the corresponding 
pharmacology review.  
Repeat dose toxicity studies were also mostly conducted in rats, mice, and monkeys 
similar to single-dose toxicity studies. Preferred species for long-term toxicology studies of 
39 or 52 weeks were mammals, including monkeys and dogs. No long-term studies 
conducted in rats were submitted. Since macimorelin is a single-dose administration drug for 
diagnosis of growth hormone deficiency, general toxicity was conducted in rats and dogs up 
to 4 weeks. However, for drugs with long-term administration such as anti-diabetics 
liraglutide and semaglutide, safety was studied for a maximum of 52 weeks in monkeys. 
For all the synthetic peptides, genotoxicity was tested using the standard battery of 
tests including the Ames test, in vitro, and in vivo genetic damage tests. The Ames test was 
mainly done on strains of E.coli and S. typhi. For icatibant, pasireotide, and macimorelin, the 
Ames test included only S.typhi strains. In vitro DNA damage in mammalian cells was tested 
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using assay of L5178Y/TK+/- mouse cells, cultured human peripheral lymphocytes, CHO-
K1 cells, or V79 cells. Most of the approved peptides included assays involving cultured 
human lymphocytes and L5178/TK+/- mouse cells. The more recently approved peptides, 
etecalcitide and macimorelin, also included aberration studies conducted in Chinese hamster 
ovarian (CHO-K1) cells and Chinese hamster lung fibroblast (V79) cells. An in vivo 
genotoxicity test was always conducted for the synthetic peptides (except linaclotide and 
macimorelin) and included either a rat or mice micronucleus test. In addition to this standard 
battery, in vivo testing was conducted for lanreotide and etecalcitide using a transgenic rodent 
model (Muta™Mouse). For macimorelin, genotoxicity was additionally assessed using the in 
silico prediction programs, DEREK evaluation and MCASE evaluation. As described in a 
2014 review of retrospective FDA approval history starting in 1998, it may not be necessary 
to conduct genotoxicity testing for peptides containing natural amino acids (Sawant, Fielden, 
& Black, 2014); it depends entirely on the molecular composition of the synthetic peptides 
whether genotoxicity evaluation is required or not.  
Carcinogenicity studies were submitted for all included synthetic peptides except for 
icatibant, carfilzomib, and macimorelin. Carcinogenicity evaluation routinely included 
testing for 2-year period in mice, rats, or both. In some cases (pasireotide, etecalcitide), 
transgenic mice were also evaluated for a 6-month duration. As carfilzomib is an anti-cancer 
pharmaceutical, carcinogenicity testing was not needed as per ICH S9; with the other two 
drugs being for intermittent (icatibant) or single (macimorelin) use, carcinogenicity 
evaluation was not needed. A more detailed carcinogenicity risk evaluation was conducted 
for semaglutide using in vitro thyroid C cell-lines and specific testing for calcitonin levels 
predictive of thyroid c-cell tumors (Guesgen et al., 2013). For liraglutide, carcinogenicity 
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evaluation included only mechanistic studies for thyroid cell tumors, but the recent molecule 
semaglutide involved more thorough evaluation. This indicates the criticality of non-clinical 
testing for carcinogenicity evaluation and changing requirements in relation to the 
advancements in the field. Thus, consultations with the FDA are crucial. 
The developmental and reproductive studies for almost all peptides were conducted 
mostly in rodents for all listed synthetic peptides. By specific parameter of toxicity 
evaluation, studies analyzing effects on reproduction or fertility (segment 1) were performed 
in mice, rats, or both. Teratology or embryo-fetal toxicity (segment 2) and pre- and post-natal 
developmental toxicity (segment 3) were also evaluated in mice, rats, and sometimes rabbits. 
For only semaglutide, teratology and pre- and post-natal developmental studies were 
additionally evaluated in monkeys. 
Among all the other non-specific studies conducted, testing for effects of impurities 
was the common category of study for six selected peptides. These tests often included 
general toxicological evaluation for impurities, mostly for a 4-week duration, and also 
genotoxicity evaluation. Apart from impurities, a series of mechanistic studies was often 
submitted with the applications that varied from case to case for peptides, depending on the 
toxicological findings from the previous non-clinical studies. For example, embryotoxicity 
was explored for semaglutide, mutagenicity was explored for etecalcitide, and T-cell 
tumorigenic potential was explored for liragutide.  
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Chapter 6: Conclusion 
Despite having only four survey respondents, the research provided some interesting 
findings. Most of the CDER reviewers agreed to share informal advice prior to IND 
submission, but only through a pre-IND meeting, and two preferred a face-to-face meeting.  
Three of the reviewers agreed that the appropriate contact person for pre-IND advice is a 
supervisory project manager, which is not known as per the literature. In the case of synthetic 
peptides, pre-IND consultation is reiterated by two reviewers for the genotoxicity testing and 
also while having issues with species selection. The second part of the research discovered 
great variability for the non-clinical studies submitted with the NDAs of the recently 
approved synthetic peptides. Further comprehensive research on variability of each type of 
safety study along with route of administration, can help to understand changing regulations 
over time. Overall, the research highlights that regular and early interactions with the FDA 
will be crucial for an optimistic response from the FDA. 
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Appendix A: Supplementary Table 
Objectives and Examples of Safety Studies 
Type of Study and Description 
Acute Toxicity  
• To determine preliminary safety of a new molecule by observing the nature and 
duration of any adverse events 
•  To find out short term adverse effects on the administration of the study drug in 
a single dose, or in multiple doses during 24 hours in two mammalian species 
(one nonrodent) through the clinical route of administration and find the 
maximum tolerated dose  
• Studies involve steadily increasing the dose (single or a number of consecutive 
doses), until adverse effects (such as vomiting and convulsions) indicating that 
an maximum tolerated dose has been reached 
• Animals are typically observed for 14 days 
 
Examples: 
Fixed Dose Procedure (OECDTG 420)  
AcuteToxic Class method (OECDTG 423)  
Up‐and‐Down Procedure (OECDTG 425)  
Acute DermalToxicity (OECDTG 402)  
Acute inhalation toxicity 
 
Sub-acute/Sub-chronic Toxicity  
• To identify adverse effects that develop over a period of continuous exposure to 
the new drug (28 days – sub acute; 90 days - subchronic)  
• To identify the most affected organs and determine the doses at which each 
effect occurs 
• Typically, of 28 days to 90 days duration, done in rats and mice  
Examples 
Repeated Dose 28‐day Oral Toxicity Study in Rodents (TG407) 
Repeated Dose 90‐Day Oral Toxicity Study in Rodents (TG 408) 
Repeated Dose Dermal Toxicity: 21/28‐day Study (TG 410) 
Subchronic Dermal Toxicity: 90‐day Study (TG 411) 
Repeated Dose Inhalation Toxicity: 28‐day or 14‐day Study (TG 412) 
Subchronic Inhalation Toxicity: 90‐day Study (TG 413) 
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Table continued 
Type of Study and Description 
Chronic Toxicity 
• To examine the cardiovascular, respiratory and CNS effects of the study drug. 
Various specific tests include: 
 
Cardiovascular 
• Dog telemetry 
• hERG assay 
• isolated Purkinje nerve fibers assays 
Respiratory 
• Evaluation of the "respiratory pump" efficiency and gas exchange 
• Whole body plethysmography -  to evaluate parameters including tidal 
volume, minute volume and mid-expiratory flow (EF50)  
CNS 
• To observed compound effects on general behavior, locomotion, 
neuromuscular coordination, seizure threshold, and vigilance through 
functional observation battery and Irwin test 
Genotoxicity  
• These tests identify compounds that can induce genetic damage 
• These are mostly required for small molecules, but not generally required for 
biologics 
Standard battery of tests include: 
• Bacterial reverse gene mutation test 
•  In vitro chromosomal aberrations using Ames test 
• In in vitro mammalian cells using the following: 
o In vitro metaphase chromosome aberration assay 
o In vitro micronucleus assay  
o mouse lymphoma L5178Y cell Tk gene mutation assay  
• In in vivo test using rodent hematopoietic cells, either for micronuclei or for 
chromosomal aberrations in metaphase cells 
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Table continued 
Type of Study and Description 
Developmental and Reproductive Toxicity  
• Teratogenecity 
Embryonic and fetal tests are usually performed in two or three species (rats, 
mice, rabbits) by administering drug to females in the initial period of pregnancy (in 
rats, 6–16 days after mating). 
• Male and Female fertility 
Fertility and implantation tests include male (28 days) and female (14 days) 
treatments with the substance before mating, and are characterized by the semen 
analysis (counting and viability), number of implanted embryos and survival of the 
embryos at the sixth day of pregnancy 
• Pre-/post-natal development 
In these tests, females are treated during pregnancy and lactation. Post-lactation 
motor activity, any abnormalities in different stages of development, their sexual 
performance and second offspring among the pups are studied 
Carcinogenicity  
• To assess the risk of cancer induction by the chemical in exposed humans 
 
• Incidence and type of the tumors that develop in rats and mice when dosed for 
up to two years (the typical lifespan)  
Note. CNS, central nervous system; OECDTG, Organisation for Economic Co-operation and Development Test 
Guidelines; hERG, human ether-a-go-go-related gene. 
From “Non-clinical studies in the process of new drug development: Part II: Good laboratory practice, 
metabolism, pharmacokinetics, safety and dose translation to clinical studies” by E. L. Andrade, A. F. Bento, 
J.Cavalli, S. K. Oliveira, R. C. Schwanke, J. M. Siqueira, C. S. Freitas, R. Marcon, and J. B. Calixto, 2016, 
Brazilian Journal of Medical and Biological Research, 49, p7–17; 
“Chapter 9: Animal use in toxicity studies”, The ethics of research involving animals. p. 155–167. London: 
Nuffield Council on Bioethics.  
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Appendix B: Questionnaire 
1)  Position at FDA 
 a. Reviewing Pharmacologist 
 b. Supervisory Pharmacologist 
 c. Other 
2)  Review Center 
 a. CDER 
 b. CBER 
 c. Other 
3)  Years at FDA 
 a. 0 to 2 
 b. 2 to 5 
 c. 6 to 10 
 d. Greater than 10 
4)  
Are you willing/able to provide informal advice to sponsors prior to 
submission of an IND 
 a. Yes 
 b. Yes, but time is extremely limited 
 c. 
Yes, but a pre-IND meeting request and supporting documentation must be 
submitted 
 d. No, an active IND must be on file 
5)  The best way to obtain advice prior to IND submission is via 
 a. Teleconference to discuss previously submitted materials 
 b. Face-to-face meeting to discuss previously submitted materials 
 c. Email replies from a project manager to very specific questions 
 d. Email replies from a reviewer to very specific questions 
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6)  The appropriate contact to request pre-IND advice is 
 a. The supervisory project manager 
 b. Any divisional project manager 
 c. The division director 
 d. Directly to a reviewing or supervisory pharmacologist 
7)  Synthetic peptides should be considered, for genotoxicity purposes,  
 a. To be handled like small molecules 
 b. To be handled like a biologic product 
 c. To vary by compound.  Pre-testing consultation should be sought. 
 d. Unknown 
8)  
If human synthetic peptides or biologics do not show the same 
pharmacology in animal models as they do in human tissue cultures, it this 
a concern for selection of species for toxicology testing? 
 a. No.  Rodent and non-rodent studies should be conducted as usual 
 b. 
No, as long as dose-limiting toxicity is above the expected human therapeutic 
dose 
 c. 
Yes, the animal model used for toxicity testing must exhibit the same 
pharmacology as that expected in humans 
 d. Pre-testing consultation with the Review Division should be sought. 
9)  
If pre-testing consultation is required before beginning toxicology tests, how 
much time should the sponsor build into their planning to allow 
appropriate input from the agency? 
 a. 1 to 2 weeks 
 b. 1 month 
 c. 2 months 
 d. More than 2 months 
10)  
Have you had personal experience dealing with issues like those mentioned 
in this survey. 
 a. Yes for issues pre-IND, but not those specific ones mentioned here. 
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 b. Yes 
 c. No 
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Appendix C: UHSRC Approval letter 
 
